Patents Assigned to Xiamen University
  • Patent number: 10309964
    Abstract: The invention belongs to the fields of medicine and immunology, particularly, the field of immunological diagnosis. In particular, the invention discloses a method for assessing whether a subject is at risk of developing human cytomegalovirus (HCMV) active infection and a kit therefore. The method comprises the steps of: (1) determining the level of an antibody against a HCMV protein in a body fluid sample from the subject; and (2) comparing the level with a predetermined reference value, wherein if the level is below the predetermined reference value, the subject is determined to be at risk of developing HCMV active infection. In addition, the invention also discloses a method for screening a candidate drug which is capable of improving the ability of a subject to resist human cytomegalovirus (HCMV) active infection, and a kit therefore.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: June 4, 2019
    Assignee: Xiamen University
    Inventors: Shengxiang Ge, Jinjie Li, Xi Huang, Tingdong Li, Jun Zhang, Ningshao Xia
  • Patent number: 10287225
    Abstract: The present invention relates to fields of organic chemistry and organometallic chemistry. The present invention discloses a chain multiyne compound, a preparation method thereof and an application in synthesizing a fused-ring metallacyclic compound. A structure of the chain multiyne compound in the present invention is shown as Formula I below. The present invention also provides a preparation method of the chain multiyne compound and an application thereof in a synthesis of a fused-ring metallacyclic compound. The chain multiyne compound disclosed in the present invention has multiple functional groups and the structure of the chain multiyne compound is adjustable. The chain multiyne compound can also be used to synthesize the fused-ring metallacyclic compound efficiently. The preparation method of the chain multiyne compound disclosed in the present invention is simple, which can be used to prepare the chain multiyne compound rapidly and efficiently.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: May 14, 2019
    Assignee: Xiamen University
    Inventors: Haiping Xia, Qingde Zhuo, Jianfeng Lin, Xiaoxi Zhou, Zhixin Chen, Yifan Shao, Hong Zhang, Xumin He
  • Patent number: 10246494
    Abstract: The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: April 2, 2019
    Assignees: Xiamen University, Yang Sheng Tang Company, Ltd.
    Inventors: Quan Yuan, Tianying Zhang, Wenxin Luo, Yixin Chen, Jun Zhang, Ningshao Xia
  • Publication number: 20190062379
    Abstract: Disclosed are a mutated HPV11 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV11 and HPV6), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. Also disclosed is use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
    Type: Application
    Filed: December 2, 2016
    Publication date: February 28, 2019
    Applicants: Xiamen University, Xiamen Innovax Biotech Co., Ltd.
    Inventors: Shaowei LI, Daning WANG, Xinlin LIU, Zhihai LI, Jun ZHANG, Ningshao XIA
  • Publication number: 20190055506
    Abstract: Disclosed are a reaction tube for nucleic acid amplification capable of controlling a liquid circulation path, a reaction apparatus for nucleic acid amplification comprising the reaction tube, and a method for amplifying nucleic acid comprising a step of using the reaction tube. Also disclosed are a kit comprising the reaction tube, and use of the reaction tube in preparation of a kit.
    Type: Application
    Filed: May 11, 2016
    Publication date: February 21, 2019
    Inventors: Shengxiang GE, Shiyin ZHANG, Feihai XU, Jin WANG, Jinjie LI, Jun ZHANG, Ningshao XIA
  • Patent number: 10189981
    Abstract: The present invention provides a method for preparing high-strength cross-linked polymer photonic crystal film by core-shell polymer microspheres via evaporation-induced self assembly. Monodispersed core-shell polymer microspheres are fabricated by emulsifier-free emulsion polymerization, and then the microspheres emulsion is coated onto suitable substrates. Finally, polymer photonic crystal film with long-range ordered is constructed via self assembly. Self-cross-linking between the two units improves the strength of the polymer photonic crystal film, therefore the preparation of large size industrial-grade photonic crystal film is practicable which extends its application on the field of dyeing.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: January 29, 2019
    Inventors: Lizong Dai, Shirong Yu, Conghui Yuan, Long Zhang, Lina Zhong, Cunfeng Song, Yiting Xu, Birong Zeng, Wei'ang Luo
  • Publication number: 20190024341
    Abstract: The identification method of the difficulty level of the operating condition of the loader, takes the excavating operation segments extracted by the operation segment as the main objects of study to identify the operating conditions, and finally get the difficulty level value of the operating condition. The identification of the difficulty level of the operating condition is beneficial to control the power output mode of diesel engine and realize the distribution according to demand; simultaneously, as the judgement basis of intelligent shift control strategy, it has great significance for intelligent shift, power mode control and improving operation performance of engineering vehicles. It is also beneficial to the improvement of the performance and the energy saving and emission reduction; at the same time, the identification of the difficulty level of the operating condition is used to realize the change of power regulation, improve the application scope of engineering machinery.
    Type: Application
    Filed: July 3, 2017
    Publication date: January 24, 2019
    Inventors: Liang HOU, Shaojie WANG, Xiangjian BU
  • Patent number: 10179331
    Abstract: A ligand based chromium catalyst and application in catalyzing ethylene oligomerization are disclosed. The chromium catalyst is formed by a chromium compound and an organic ligand containing P and/or N. The substituents on N and P of the ligand can be replaced, whereby selective ethylene trimerization and tetramerization can be realized so as to produce 1-hexene and 1-octene at the same time.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: January 15, 2019
    Inventors: Xianghong Zhong, Hongping Zhu, Xiaofeng Ye, Yucai Cao, Shengbiao Liang, Zhenyu Liu, Shumeng Xiao, Rui Liu, Yanfang Huang, Jiancheng Li
  • Patent number: 10174015
    Abstract: The present invention relates to a class of substituted heterocyclic derivative and preparation method thereof.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: January 8, 2019
    Assignee: Xiamen University
    Inventors: Zuguo Liu, Yan Qiu, Jie Ren, Yuhang Li, Longhe Yang, Chenggang Zhu
  • Publication number: 20180312508
    Abstract: The present invention relates to a compound of formula I, a stereoisomer, a prodrug, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a process for preparing the same, a pharmaceutical composition comprising the same, and use of the compound in the preparation of medicine preventing and treating tumors, wherein the substituents are as defined in the specification.
    Type: Application
    Filed: April 25, 2016
    Publication date: November 1, 2018
    Applicant: Xiamen University
    Inventors: Xianming DENG, Zhongji ZHUANG, Zhou DENG, Xuaixing HUANG, Yan LIU, Ting ZHANG, Wei HUANG, Qingyan XU, Zhiyu HU
  • Publication number: 20180311143
    Abstract: The present invention provides a skin penetration enhancing method and its penetration enhancer which is comprised of sponge spicules or a biologically effective amount of sponge spicules or a combination containing sponge spicules. The penetration enhancer can be applied onto the skin to overcome the skin stratum corneum barrier, which can increase the percutaneous absorption of drugs, vaccines and cosmetics into different skin layers or can improve the transdermal delivery of all these therapeutics into the systemic blood circulation. This technology can be used for dermal delivery of therapeutics into the skin or for transdermal delivery of therapeutics across the skin into systemic blood circulation.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 1, 2018
    Inventors: Ming CHEN, Dexiang WANG
  • Patent number: 10087156
    Abstract: Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenviroment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 2, 2018
    Inventors: Xiao-kun Zhang, Ying Su, Hu Zhou, Wen Liu, Pei-Qiang Huang
  • Patent number: 10052340
    Abstract: The present invention relates to the new use of antiparasitic agents, such as ivermectin, abamectin/avermectin, doramectin and so on, and the design method of the derivatives for the new use. The said compounds including macrolide abamectin/avermectin, ivermectin, doramectin and the derivatives thereof, may be used in the manufacture of a medicament for use in treating metabolic related diseases in a mammal, such as hyperglycemia, insulin resistance, hypertriglyceridemia, hypercholesterolemia, diabetes, obesity, etc, and Famesoid X receptor mediated diseases, such as cholestasia, gallstone, non alcohol fatty liver disease, atherosclerosis, inflammation, cancer, etc.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: August 21, 2018
    Inventors: Yong Li, Lihua Jin, Xuhui Feng
  • Publication number: 20180226624
    Abstract: A modified ceramic composite separator includes an organic support layer and a ceramic layer coated on the surface of the support layer in a thickness of 0.1 ?m to 20 ?m, and further comprises a dopamine or other polymer grown in-situ on the surface and interior of the support layer and the ceramic layer. The inorganic power in the ceramic layer has a particle size of 5 nm to 10 ?m, and the material of the organic support layer has a molecular weight of 1000 to 100000000.
    Type: Application
    Filed: August 24, 2016
    Publication date: August 9, 2018
    Inventors: Jinbao ZHAO, Peng ZHANG, Chuan SHI, Jianhui DAI
  • Patent number: 9974868
    Abstract: Disclosed are nanoparticles comprising octapod iron oxide having eight trigonal bipyramidal arms and a method of preparing the same. The nanoparticles are prepared by heating a mixture of a ferric carboxylate, a carboxylic acid, a chloride salt, water, and a non-polar solvent, to a temperature above about 300° C. Also disclosed is a method of magnetic resonance imaging a tissue in a mammal, comprising use of the aforesaid nanoparticles.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: May 22, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Xiamen University
    Inventors: Jinhao Gao, Xiaoyuan Chen, Zenghuan Zhao
  • Publication number: 20180116993
    Abstract: Compounds, compositions and methods are provided for treating the FXR-mediated disease or process in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound claimed, wherein the FXR-mediated disease or condition linked to chronic liver diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; gastrointestinal diseases; cardiovascular diseases; metabolic diseases such as diabetes and obesity; inflammation, or cancer etc.
    Type: Application
    Filed: January 21, 2016
    Publication date: May 3, 2018
    Inventors: Yong LI, Lihua JIN, Weili ZHENG, Yanlin ZHU, Fusheng GUO
  • Patent number: 9952217
    Abstract: The present invention relates to a method for quantitative detection of anti-HBc and its use in monitoring disease progression of chronic hepatitis B patients and predicting therapeutic effects. By quantitative detection of antibodies against hepatitis B core protein (Anti-HBc), it is able to monitor disease progression of chronic hepatitis B patients, effectively predict therapeutic effects in chronic hepatitis B patients who accept a therapy against hepatitis B virus (especially, a therapy based on interferon and a therapy based on nucleoside/nucleotide analog anti-HBV drug), and thus guide the patients to reasonably choose drugs.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: April 24, 2018
    Assignees: Xiamen Innovax Biotech, Co., LTD., Xiamen University
    Inventors: Quan Yuan, Liuwei Song, Wenbin Zhou, Zuxing Weng, Feihai Xu, Shengxiang Ge, Jun Zhang, Ningshao Xia
  • Patent number: 9943586
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: April 17, 2018
    Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
  • Publication number: 20180099360
    Abstract: A method for accurately producing the drilled hole in a wall of a component fabricated by investment casting process, such as for use in a blade or steam turbine includes the following steps. The 3D data of actual component is obtained from the measurements or from the numerical simulation. The actual model and the ideal model are aligned and compared, a series of cutting planes are given to establish a series of 2D cross-sections of the actual and ideal models after registration. Each cross-section is dispersed into discrete points, the distance between each corresponding points are calculated and formed into 2D displacement. The accurate parametric model consisting of the depth, hole center, and the nominal vector is obtained on the basis of considering the deviations in geometrical and positional values. The drilled hole is then produced according to the corrected parametric drilled-hole geometrical and positional value.
    Type: Application
    Filed: October 5, 2017
    Publication date: April 12, 2018
    Inventors: Yiwei DONG, Yancheng YOU, Chunping YIN, Xiaoji LI, Qi ZHAO, Ertai WANG, Zongpu WU
  • Publication number: 20180093228
    Abstract: This present disclosure relates to a method for preparation of polyvinylidene fluoride membrane with functional anthraquinones. The method is carried out according, to the following steps: step 1: preparing 2-(1-hydroxy-3-butene)-1,4,5,8-tetramethoxyl naphthalene; step 2: preparing polyvinylidene fluoride-aromatic ether copolymers: polyvinylidene fluoride was used as the initiator, 2-(1-hydroxy-3-butene) -1,4,5,8-tetramethoxynaphthalene was the monomer, N,N-dimethylformamide was solvent, cuprous chloride/Me6TREN was the catalytic, polyvinylidene fluoride-aromatic ether copolymer was synthesized by atomic transfer radical polymerization; step 3: reducing the polyvinylidene fluoride-aromatic ether copolymer to quinone by demethoxy oxidation; step 4: using the product of step 3 and N, N-dimethylformamide a film-forming reagents, then scraping into a membrane. Further, the anthraquinone which fixed in the polyvinylidene fluoride membrane would not fall off.
    Type: Application
    Filed: November 24, 2017
    Publication date: April 5, 2018
    Inventors: Bin YAN, Yuping WANG, Qian YE